Fig. 8
From: RBM47 is a novel immunotherapeutic target and prognostic biomarker in gliomas
Prediction model. (A) Nomogram of RBM47 and other prognostic factors in TCGA database. (B) Calibration chart showing the predicted survival probabilities in the training and validation groups. (C) C-index evaluation of prediction model’s predictive performance.
